The iFuse is designed for treatment of sacroiliac joint disruptions or degenerative sacroiliitis. The article contains a study of 50 patients treated with the minimally invasive titanium implant and evaluated for pain and functional outcomes.
The study showed complication rates were low and 80 percent of patients would have the same surgery again, according to the release.
The iFuse implant has been given to 5,000 patients since 2009.
More Articles on Devices:
Blue Belt’s Unicondylar Knee Replacement System Receives FDA Clearance
NuVasive Fusion Cages Receive Japanese Approval
12 Orthopedic Device Company Leadership Moves
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.